Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: teriparatide
INDICATION: Osteoporosis
DATE: 31/01/2019
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
